market appreci guidanc amidst volatil
report revenu morn repres y/i growth
upsid compani april pre-announc full year guidanc lower
suspend appreci visibl believ warrant slightli higher
multipl ep previoulsi assign reiter neutral rate rais
price target base prior ep
low water mark ds segment main stage contribut
total compani revenu oper profit bear brunt
impact global clinic trial site inaccess
today despit heighten demand virtual trial solut like econs ecoa
on-sit activ shut mileston get delay headwind
number howev data china suggest recoveri
europ fairli shape compani believ new case viru
begin declin end site back
expect higher long term profit ds segment increas scope
qualiti remot capabl sinc start pandem compani
see remot monitor level vs pre-covid pioneer
risk base monitor market offer biopharma client industry-lead
hybrid trial orchestr sinc least trial may support virtual
orchestr believ major trial lend hybrid approach
emphas remot monitor still entail degre on-sit activ believ
catalyst meaning acceler risk base monitor
broadened/ improv remot capabl like home lab draw way telehealth
visit multi-lingu studi hub support continu reson
subsid allow hybrid trial offer take share next year
time frame believ mix shift on-sit remot monitor
activ within trial posit gross oper margin ds
number revenu guid y/i
adjust ebitda margin midpoint full year revenu guidanc came
y/i adjust ebitda
margin midpoint impli decrement expect
covid impact hit remain base
manag commentari expect impact temporari
model robust revenu catch-up ta ds first half follow
modest recoveri resum buy-back back half
 spend volatil revers current outsourc trend high leverag
iqvia largest cro industri expertis across major therapeut
ep
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
guidanc vs psc consensu
page
estreportedvary/yv net adj ebjtda adj fy guidanc mid prior guidanc mid psc consensusrevenu adj ebjtda adj iqvia
revenu
depreci amort
incom oper
loss extinguish debt
incom tax
equiti earn unconsolid affili
incom attribut non control interest
total revenu
incom oper
equiti earn unconsolid affili
loss incom non control interest
current disclosur inform compani locat http /www pipersandl com/disclosur
